Overall survival of patients in the recent cohort stratified by level of MRD
| MRD status . | AML (n = 44) . | ALL (n = 33) . | ||
|---|---|---|---|---|
| n . | 5-year estimate (95% CI) . | n . | 5-year estimate (95% CI) . | |
| < 0.01% | 27 | 80.4 (53.9-92.6) | 18 | 87.5 (58.6-96.7) |
| 0.01%- < 5.0% | 9 | 66.7 (28.2-87.8) | 13* | 48.5 (17.9-73.7) |
| ≥ 5.0% | 8 | 58.3 (18.0-84.4) | 2 | 0 |
| MRD status . | AML (n = 44) . | ALL (n = 33) . | ||
|---|---|---|---|---|
| n . | 5-year estimate (95% CI) . | n . | 5-year estimate (95% CI) . | |
| < 0.01% | 27 | 80.4 (53.9-92.6) | 18 | 87.5 (58.6-96.7) |
| 0.01%- < 5.0% | 9 | 66.7 (28.2-87.8) | 13* | 48.5 (17.9-73.7) |
| ≥ 5.0% | 8 | 58.3 (18.0-84.4) | 2 | 0 |
The 5-year survival was 66.7% (95% confidence interval [CI], 19.5%-90.4%) for the 6 patients with MRD between 0.01% and < 0.1%, and 42.9% (95% CI, 9.8%-73.4%) for the 7 patients with MRD between 0.1% and < 5%.